Abstract
The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Anti-Cancer Agents in Medicinal Chemistry
Title: SHP-1 in Cell-Cycle Regulation
Volume: 11 Issue: 1
Author(s): Pilar Lopez-Ruiz, Javier Rodriguez-Ubreva, Ariel Ernesto Cariaga, Maria Alicia Cortes and Begona Colas
Affiliation:
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Abstract: The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Export Options
About this article
Cite this article as:
Lopez-Ruiz Pilar, Rodriguez-Ubreva Javier, Ernesto Cariaga Ariel, Alicia Cortes Maria and Colas Begona, SHP-1 in Cell-Cycle Regulation, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941154
DOI https://dx.doi.org/10.2174/187152011794941154 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topoisomerase I and II Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry Gene Electrotransfer: A Mechanistic Perspective
Current Gene Therapy Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents
Drug Design Reviews - Online (Discontinued) DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Anticancer Potential of Pulicaria crispa Extract on Human Breast Cancer MDA-MB-231 Cells
Letters in Drug Design & Discovery The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection
Current Topics in Medicinal Chemistry High Throughput Screening for Drug Discovery of Autophagy Modulators
Combinatorial Chemistry & High Throughput Screening Polypurine Reverse Hoogsteen Hairpins as a Gene Silencing Tool for Cancer
Current Medicinal Chemistry Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations
Current Medicinal Chemistry Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status
Current Cancer Drug Targets Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry